{"id":984,"date":"2023-04-17T14:56:28","date_gmt":"2023-04-17T14:56:28","guid":{"rendered":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/"},"modified":"2023-12-14T15:43:32","modified_gmt":"2023-12-14T15:43:32","slug":"cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding","status":"publish","type":"post","link":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/","title":{"rendered":"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding"},"content":{"rendered":"<p><span class=\"text-small\">Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in\u00a0<a href=\"https:\/\/complementtx.com\/\" target=\"_blank\" rel=\"noopener\">Complement Therapeutics<\/a>\u2019 \u20ac72 Million Series A funding round led by Gimv and co-led by Forbion, alongside existing investor BioGeneration Ventures and new investors Panak\u00e8s, Hadean Ventures and Seroba Life Sciences.<\/span><\/p>\n<p><span class=\"text-small\">Complement Therapeutics GmbH (CTx) is a preclinical stage biotechnology company with research laboratories in Stevenage, UK., which is developing novel therapeutics for complement-mediated diseases &#8211; chronic, rare, complex, and progressive diseases that occur when the human body\u2019s immune system becomes overly active.<\/span><\/p>\n<p><span class=\"text-small\">The investment will be used to further develop and complete a Phase 1b clinical proof of concept trial of CTx\u2019s lead product &#8211; a highly innovative AAV gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry age-related macular degeneration (dry-AMD). Additionally, funds will be deployed to grow CTx\u2019s laboratory-based activities, and further advance the company\u2019s range of novel therapeutics alongside the development of its Complement Precision Medicine (CPM) platform.<\/span><\/p>\n<p><span class=\"text-small\">CTx is developing novel therapeutics for complement mediated diseases. Its lead product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. CTx\u2019s team is evaluating potential therapeutic opportunities in several other complement-mediated conditions. The company is also developing a unique quantification methodology, the CPM platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.<\/span><\/p>\n<p><span class=\"text-small\">\u201cWith a potentially highly differentiated lead asset combined with a precision medicine approach, we are excited by the opportunity to further develop CTx001 for the treatment of GA through to the clinic.\u201d said Dr Rafiq Hasan, CEO and Managing Director at Complement Therapeutics GmbH. \u201cThe support of this broad syndicate enables us to generate additional data demonstrating CTx001\u2019s unique and differentiated mechanism of action, with the potential to transform the treatment landscape in geographic atrophy.\u201d<\/span><\/p>\n<p><span class=\"text-small\"><strong>Anne Horgan, Partner at Cambridge Innovation Capital,<\/strong>\u00a0who will join CTx\u2019s board, said:<\/span><\/p>\n<p>&#8220;We are delighted to join Complement Therapeutics\u2019 Series A financing alongside such a strong syndicate. The field of GA is one that we know well at CIC and a clear area of unmet patient need. Dr Hasan and his team\u2019s combination of strong industry experience and deep understanding of complement-mediated conditions means CTx is extremely well placed to develop novel therapies for patients suffering from GA and potentially other complement-mediated diseases. We look forward to working with the CTx team and supporting the company in the next phase of its journey.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in\u00a0Complement Therapeutics\u2019 \u20ac72 Million Series A funding round led by Gimv and co-led by Forbion, alongside existing investor BioGeneration Ventures and new investors Panak\u00e8s, Hadean Ventures and Seroba Life Sciences. Complement Therapeutics GmbH (CTx) [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":3018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[5,29],"tags":[49],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding - Cambridge Innovation Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding - Cambridge Innovation Capital\" \/>\n<meta property=\"og:description\" content=\"Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in\u00a0Complement Therapeutics\u2019 \u20ac72 Million Series A funding round led by Gimv and co-led by Forbion, alongside existing investor BioGeneration Ventures and new investors Panak\u00e8s, Hadean Ventures and Seroba Life Sciences. Complement Therapeutics GmbH (CTx) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Cambridge Innovation Capital\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T14:56:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-14T15:43:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lewis Harrison-Pinder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:site\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lewis Harrison-Pinder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/\",\"url\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/\",\"name\":\"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding - Cambridge Innovation Capital\",\"isPartOf\":{\"@id\":\"https:\/\/www.cic.vc\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp\",\"datePublished\":\"2023-04-17T14:56:28+00:00\",\"dateModified\":\"2023-12-14T15:43:32+00:00\",\"author\":{\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#primaryimage\",\"url\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp\",\"contentUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp\",\"width\":2560,\"height\":1707,\"caption\":\"A closeup of a female face wearing transparent virtual reality glasses with dna image model reflection on them. The concept of innovative future medicine technologies.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cic.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cic.vc\/#website\",\"url\":\"https:\/\/www.cic.vc\/\",\"name\":\"Cambridge Innovation Capital\",\"description\":\"We enable visionaries to build global, category-leading companies.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cic.vc\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc\",\"name\":\"Lewis Harrison-Pinder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g\",\"caption\":\"Lewis Harrison-Pinder\"},\"url\":\"https:\/\/www.cic.vc\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding - Cambridge Innovation Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/","og_locale":"en_GB","og_type":"article","og_title":"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding - Cambridge Innovation Capital","og_description":"Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in\u00a0Complement Therapeutics\u2019 \u20ac72 Million Series A funding round led by Gimv and co-led by Forbion, alongside existing investor BioGeneration Ventures and new investors Panak\u00e8s, Hadean Ventures and Seroba Life Sciences. Complement Therapeutics GmbH (CTx) [&hellip;]","og_url":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/","og_site_name":"Cambridge Innovation Capital","article_published_time":"2023-04-17T14:56:28+00:00","article_modified_time":"2023-12-14T15:43:32+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp","type":"image\/jpeg"}],"author":"Lewis Harrison-Pinder","twitter_card":"summary_large_image","twitter_creator":"@cic_vc","twitter_site":"@cic_vc","twitter_misc":{"Written by":"Lewis Harrison-Pinder","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/","url":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/","name":"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding - Cambridge Innovation Capital","isPartOf":{"@id":"https:\/\/www.cic.vc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#primaryimage"},"image":{"@id":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp","datePublished":"2023-04-17T14:56:28+00:00","dateModified":"2023-12-14T15:43:32+00:00","author":{"@id":"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc"},"breadcrumb":{"@id":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#primaryimage","url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp","contentUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/Complement-Tx-AdobeStock_260942453-1-scaled.webp","width":2560,"height":1707,"caption":"A closeup of a female face wearing transparent virtual reality glasses with dna image model reflection on them. The concept of innovative future medicine technologies."},{"@type":"BreadcrumbList","@id":"https:\/\/www.cic.vc\/cambridge-innovation-capital-invests-in-complement-therapeutics-e72-million-series-a-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cic.vc\/"},{"@type":"ListItem","position":2,"name":"Cambridge Innovation Capital invests in Complement Therapeutics\u2019 \u20ac72 Million Series A Funding"}]},{"@type":"WebSite","@id":"https:\/\/www.cic.vc\/#website","url":"https:\/\/www.cic.vc\/","name":"Cambridge Innovation Capital","description":"We enable visionaries to build global, category-leading companies.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cic.vc\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc","name":"Lewis Harrison-Pinder","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g","caption":"Lewis Harrison-Pinder"},"url":"https:\/\/www.cic.vc\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/984"}],"collection":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/comments?post=984"}],"version-history":[{"count":3,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/984\/revisions"}],"predecessor-version":[{"id":3019,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/984\/revisions\/3019"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media\/3018"}],"wp:attachment":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media?parent=984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/categories?post=984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/tags?post=984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}